India, Oct. 16 -- As a part of its long term strategy to build a global innovation-led pharmaceutical business, Mankind Pharma, through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer.

Mankind will invest EUR 48 million for 70% stake in Armed Cell Therapeutics (ACTx) which has a pipeline of next-generation CAR-T assets, with lead programmes in non-Hodgkin lymphoma and small cell lung cancer. ACTx will pursue innovative means of CAR- T cell therapy including in vivo CAR-T cell ...